Bioventus (BVS) reported fiscal Q2 adjusted earnings Wednesday of $0.22 per diluted share, up from $0.21 a year earlier.
Analysts polled by FactSet expected $0.22.
Revenue for the three months ended June 27 was $153.2 million, up from $147.7 million a year earlier.
Analysts expected $155.4 million.
The company reiterated its full-year 2026 adjusted EPS guidance of $0.75 to $0.79 and revenue of $600 million to $610 million.
Analysts expect $0.78 and $605.3 million, respectively.
Shares of Bioventus were up more than 12% in Wednesday trading.
Price: 15.09, Change: +1.67, Percent Change: +12.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.